Unichem Laboratories Limited (IN:UNICHEMLAB)
:UNICHEMLAB
UNICHEMLAB Stock Chart & Stats
₹443.05
-₹12.85(-1.76%)
At close: 4:00 PM EST
₹443.05
-₹12.85(-1.76%)
Day’s Range― - ―
52-Week Range₹280.00 - ₹668.00
Previous CloseN/A
Volume14.19K
Average Volume (3M)1.03K
Market Cap
₹23.22B
Enterprise Value₹26.42B
Total Cash (Recent Filing)₹1.94B
Total Debt (Recent Filing)₹5.02B
Price to Earnings (P/E)2.9
Beta1.10
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)37.54
Shares Outstanding70,405,754
10 Day Avg. Volume1,013
30 Day Avg. Volume1,033
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)2.00
Price to Sales (P/S)2.32
P/FCF Ratio-33.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth (18.18% 5-year trend) demonstrates durable demand and successful market expansion across domestic branded formulations, exports and API sales. This scale improves bargaining power, spreads fixed costs and supports reinvestment in R&D and manufacturing over the medium term.
Improved Gross MarginA materially higher gross margin reflects improved production efficiency or a favorable product mix (shift to higher-margin formulations/APIs). Sustained gross margin expansion underpins long-term operating leverage, giving the company room to invest in growth while protecting profitability against input-cost cycles.
Low Leverage / Strong EquityVery low leverage and rising equity provide financial flexibility to fund capex, regulatory filings, geographic expansion or absorb shocks without compromising operations. This balance-sheet strength reduces refinancing risk and supports long-term strategic initiatives in regulated pharma markets.
Bears Say
Negative Operating Cash FlowOperating cash flow turning negative and persistent negative free cash flow signal weak cash conversion despite revenue growth. This undermines the firm's ability to self-fund capex, regulatory approvals and working capital, increasing reliance on external financing or equity issuance over the medium term.
Modest Net ProfitabilityA low net margin despite strong top-line growth indicates limited operating leverage or high SG&A/R&D and pricing pressure in competitive markets. Persistently modest margins constrain retained earnings for reinvestment and make earnings more sensitive to cost inflation or reimbursement/regulatory shifts.
Volatile Operating MarginsVolatility in EBIT/EBITDA margins points to inconsistent cost control, product-mix swings or exposure to pricing dynamics across markets. This increases execution risk for multi-market pharmaceutical operations and complicates forecasting, capital allocation and sustainable margin improvement plans.
Unichem Laboratories Limited News
UNICHEMLAB FAQ
What was Unichem Laboratories Limited’s price range in the past 12 months?
Unichem Laboratories Limited lowest stock price was ₹280.00 and its highest was ₹668.00 in the past 12 months.
What is Unichem Laboratories Limited’s market cap?
Unichem Laboratories Limited’s market cap is ₹23.22B.
When is Unichem Laboratories Limited’s upcoming earnings report date?
Unichem Laboratories Limited’s upcoming earnings report date is May 21, 2026 which is in 42 days.
How were Unichem Laboratories Limited’s earnings last quarter?
Unichem Laboratories Limited released its earnings results on Feb 05, 2026. The company reported ₹37.538 earnings per share for the quarter, beating the consensus estimate of N/A by ₹37.538.
Is Unichem Laboratories Limited overvalued?
According to Wall Street analysts Unichem Laboratories Limited’s price is currently Overvalued.
Does Unichem Laboratories Limited pay dividends?
Unichem Laboratories Limited pays a Annually dividend of ₹4 which represents an annual dividend yield of N/A. See more information on Unichem Laboratories Limited dividends here
What is Unichem Laboratories Limited’s EPS estimate?
Unichem Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Unichem Laboratories Limited have?
Unichem Laboratories Limited has 70,405,754 shares outstanding.
What happened to Unichem Laboratories Limited’s price movement after its last earnings report?
Unichem Laboratories Limited reported an EPS of ₹37.538 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.969%.
Which hedge fund is a major shareholder of Unichem Laboratories Limited?
Currently, no hedge funds are holding shares in IN:UNICHEMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Unichem Laboratories Limited
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. It offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients, as well as contract manufacturing services. The company was founded in 1944 and is headquartered in Mumbai, India.
Technical Analysis
Aarti Drugs Limited
―
Dishman Carbogen Amcis Ltd.
―
Gufic Biosciences Limited
―
RPG Life Sciences Limited
―
―